SMN Transcript Stability: Could Modulation of Messenger RNA Degradation Provide a Novel Therapy for Spinal Muscular Atrophy?

Abstract

Proximal spinal muscular atrophy is caused by deletion or mutation of the survival motor neuron 1 gene, SMN1. Rentention of a nearly identical copy gene, SMN2, enables survival but is unable to fully compensate for the loss of SMN1. The SMN1 and SMN2 genes differ by a single nucleotide that results in alternative splicing of SMN2 exon 7 due to the disruption of a binding site for an essential splicing factor. This alternatively spliced form encodes a partially functional truncated protein. Because SMN2 is present in patients with spinal muscular atrophy, it is an ideal therapeutic target. Some of the current approaches to increase SMN protein levels are aimed at increasing the transcription from SMN2 or at preventing exon 7 skipping. One area that has yet to be investigated is the stability of messenger ribonucleic acid (RNA) transcripts produced from SMN2. We postulated that transcripts derived from SMN2 may be less stable because alternative splicing, recruitment of RNA-binding proteins, and alteration of stop codons have been associated with changes in rates of messenger RNA decay; these features are all characteristic of SMN2. Accordingly, transcript degradation was examined within primary fibroblast cells that exclusively contained SMN1 or SMN2 by treating cultures with a transcriptional inhibitor to observe messenger RNA stability. The results indicate that SMN transcript instability does not play a role in the disease mechanism, suggesting that therapeutic modulation of messenger RNA degradation would not target a molecular defect in patients with spinal muscular atrophy, although it could provide general benefits by increasing total pools of SMN2 transcripts.

Keywords

spinal muscular atrophy SMN1 gene SMN2 gene

Get full access to this article

View all access options for this article.

References

Crawford TO , Pardo CA The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996;3(2):97-110.

Rochette CF , Gilbert N. , Simard LR SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet. 2001;108(3): 255-266.

Lefebvre S. , Burglen L. , Reboullet S. , et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165.

Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228-237.

Lorson CL , Hahnen E. , Androphy EJ , Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96(11):6307-6311.

Cartegni L. , Hastings ML , Calarco JA , et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006 ;78(1):63-77.

Cartegni L. , Krainer AR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30(4):377-384.

Lorson CL , Androphy EJ An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet. 2000;9(2):259-265.

Lorson CL , Strasswimmer J. , Yao JM , et al. SMN oligomerization defect correlates with spinal muscular atrophy severity [letter]. Nat Genet. 1998;19(1):63-66.

10.

Coovert DD , Le TT , McAndrew PE , et al. The survival motor neuron protein in spinal muscular atrophy . Hum Mol Genet. 1997;6(8):1205-1214.

11.

Feldkotter M. , Schwarzer V. , Wirth R. , et al. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2): 358-368.

12.

Hsieh-Li HM , Chang JG , Jong YJ , et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24(1):66-70.

13.

McAndrew PE , Parsons DW , Simard LR , et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997; 60(6):1411-1422.

14.

Sumner CJ Therapeutics development for spinal muscular atrophy. NeuroRx . 2006;3(2):235-245.

15.

Caceres JF , Screaton GR , Krainer AR A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 1998;12(1):55-66.

16.

Lemaire R. , Prasad J. , Kashima T. , et al. Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev. 2002;16(5):594-607.

17.

Thiele A. , Nagamine Y. , Hauschildt S. , Clevers H. AU-rich elements and alternative splicing in the β-catenin 3'UTR can influence the human β-catenin mRNA stability. Exp Cell Res. 2006;312(12):2367-2378.

18.

Vela E. , Roca X. , Isamat M. Identification of novel splice variants of the human CD44 gene. Biochem Biophys Res Commun. 2006;343(1):167-170.

19.

Grellscheid SN , Smith CW An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon. Mol Cell Biol. 2006;26(6):2237-2246.

20.

Le Hir H. , Gatfield D. , Izaurralde E. , Moore MJ The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J. 2001;20(17):4987-4997.

21.

Reed R. Coupling transcription, splicing and mRNA export. Curr Opin Cell Biol. 2003;15(3):326-331.

22.

Culbertson MR , Neeno-Eckwall E. Transcript selection and the recruitment of mRNA decay factors for NMD in Saccharomyces cerevisiae. RNA . 2005;11(9):1333-1339.

23.

He F. , Li X. , Spatrick P. , et al. Genome-wide analysis of mRNAs regulated by the nonsense-mediated and 5' to 3' mRNA decay pathways in yeast. Mol Cell. 2003;12(6):1439-1452.

24.

Eberhardt W. , Doller A. , Akool ES , Pfeilschifter J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114(1):56-73.

25.

Mifflin RC , Saada JI , Di Mari JF , et al. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol . 2004;65(2):470-478.

26.

Tong X. , Van Dross RT , Abu-Yousif A. , et al. Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition. Mol Cell Biol. 2007; 27(1):283-296.

27.

Lai WS , Parker JS , Grissom SF , et al. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol Cell Biol. 2006; 26(24):9196-9208.

28.

Sumner CJ , Huynh TN , Markowitz JA , et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54(5):647-654.

29.

Andreassi C. , Angelozzi C. , Tiziano FD , et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004;12(1):59-65.

30.

Livak KJ , Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25(4):402-408.

31.

Gennarelli M. , Lucarelli M. , Capon F. , et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun. 1995;213(1):342-348.

32.

Poulalhon N. , Farge D. , Roos N. , et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin: a direct role as an antifibrotic agent? J Biol Chem. 2006;281(44):33045-33052.

33.

Frugier T. , Tiziano FD , Cifuentes-Diaz C. , et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2000;9(5):849-858.

34.

Le TT , Pham LT , Butchbach ME , et al. SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005;14(6):845-857.

35.

Mattis VB , Rai R. , Wang J. , et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet. 2006;120(4):589-601.

36.

Wolstencroft EC , Mattis V. , Bajer AA , et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet. 2005;14(9):1199-1210.